Dmitry Balyasny’s Immuneering IMRX Stock Holding History

Dmitry Balyasny’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,366	Closed	-$163K	–	2987
2022 Q3	$163K	Buy	+11,366	New	+$90.3K	﹤0.01%	2343

Other funds holding IMRX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Dmitry Balyasny's IMRX Position: Q4 2022 in Review

Dmitry Balyasny sold out of Immuneering (IMRX) in Q4 2022, closing a stake of 11,366 shares — an estimated $163K sold.

Dmitry Balyasny first reported a position in IMRX in Q3 2022 and held it in 1 quarter. The position peaked at $163K in Q3 2022. 34 funds tracked by Wall St. Rank hold IMRX as of Q4 2022.

Dmitry Balyasny reported no remaining Immuneering position as of Q4 2022 after selling out during the quarter.
Dmitry Balyasny sold 11,366 Immuneering shares in Q4 2022, an estimated $163K.
Dmitry Balyasny first reported a position in Immuneering in Q3 2022 and held it in 1 quarter.
Dmitry Balyasny's Immuneering position peaked at $163K in Q3 2022.
34 funds tracked by Wall St. Rank held Immuneering as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.